lotrevaWhat is retatrutide?
Retatrutide is an investigational molecule that activates three receptor systems: GIP, GLP-1 and glucagon. Lilly is developing it through a clinical research program. “Triple agonist” describes this mechanism; it does not mean three medicines have been mixed together, or that a material sold under the same name has been evaluated in that program.
An evidence map, not a product claim.
Start a literature review by separating what a molecule is proposed to do from what a study actually measured. Keep the publication, study population, endpoint and follow-up period in the same record. A mechanistic explanation cannot stand in for a clinical outcome.
| Evidence type | Question addressed | What does not follow automatically |
|---|---|---|
| Receptor activity | Which biological targets are engaged? | Clinical benefit or long-term safety |
| Controlled clinical study | What happened in the selected participants under a protocol? | The result for every person or setting |
| Analytical report for a material | What was measured in the submitted sample? | Equivalence to the trial medicine |
| Regulatory decision | Which finished product and use were reviewed? | Approval of similarly named research materials |
Published trials answer specific questions.
The 2023 Phase 2 obesity trial randomized 338 adults and assessed weight change over a defined follow-up, with a primary endpoint at 24 weeks and further assessment at 48 weeks. The report also describes adverse events, including gastrointestinal events and changes in heart rate. It should be read as a controlled trial, not as a forecast for an individual.
Sources: Jastreboff et al. (2023): randomized retatrutide Phase 2 obesity trial
Current status: checked September 12, 2026.
The development program has advanced beyond Phase 2. Lilly’s July 2026 update describes Phase 3 disclosures across TRIUMPH and TRANSCEND-T2D studies. These are different populations and clinical questions. The sponsor update is useful for locating newer evidence, but it is not a substitute for each complete publication and its analysis plan.
FDA states that retatrutide is not a component of an approved drug and cannot be used in compounding under federal law. Research-use labeling does not establish an approved medical use.
Sources: Lilly: retatrutide development update (July 2026); FDA: concerns with unapproved GLP-1 drugs
A useful next reading step.
Choose one question before collecting results: receptor pharmacology, a specified clinical endpoint, or analytical identity. Then record which document would resolve that question and what remains unknown. If the available evidence is only an abstract or sponsor announcement, retain that limitation in the notes rather than presenting it as a full independent appraisal.
This article summarizes research context. It provides no personal-use instructions and establishes no quality, identity or clinical equivalence for Lotreva materials.